Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025.
6 reports, 4 independent
Updated Aug 17
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 6
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Application for zorevunersen is seeking a pre-NDA meeting with the FDA.1 source
- Andreas Brunklaus, a consultant in Glasgow, is involved in studies of zorevunersen.Sub-event
Jointly presented data on zorevunersen trials.1 source
Collaboration between Biogen and Stoke Therapeutics enhances global delivery of zorevunersen.1 source
Keep exploring
The entities involved
-
Biogen
American multinational biotechnology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- tickerreport.com
- Business WireStoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome – Dur
- GuruFocus.comStoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... Cash, Cash Equivalents, and Marketable Securities: $355 million as of the end of the second quarter. To
- Clinical Trials ArenaFirst patient dosed in Phase III trial of zorevunersen for Dravet syndrome Stoke Therapeutics and Biogen have dosed the first subject in the global, double-blind Phase III EMPEROR trial of the invest